SDIC Venture Capital
国投创业
SDIC Venture Capital (国投创业) is a state-backed investment fund active in China's venture capital market, particularly prominent in healthcare and new energy. Per a 2023 暗涌Waves analysis, it sits among the most active state-affiliated investors in the new energy sector alongside entities like SDIC Innovation and SDIC Chuangyi . In practice, it operates as a lead investor in growth-stage rounds: it led the 700 million RMB Series A of Yanming Biotech in 2023 and the 100 million+ RMB A+ round of Kailan Pharma in early 2025 , and participated in Haichang Biotech's nearly 500 million RMB Series C later that year . Its capital also flows into strategic industrial deals, as seen in its co-investment in Xindi Digital's 700 million RMB club deal alongside BYD's strategic investment arm .
AI-generated — may contain errors, please verify.
Coverage
Haichang Biotech Closes Nearly 500 Million Yuan Series C Round to Accelerate Development of Innovative Nucleic Acid Drugs and Complex Injectables
Focused on the R&D and industrial application of drug delivery system technologies.
Rongbao | Generative AI and medical device companies close new funding rounds, setting domestic records in their respective sectors
The Power of Aspiration.
Kailan Pharma Closes Oversubscribed A+ Round of Over 100 Million RMB to Advance Cholesterol Metabolism Drug R&D
Striving to provide alternative treatment options for patients with metabolic diseases.
Autumn's Prime: Six FreeS Fund Early-Stage Portfolio Companies Raise Nearly 1 Billion RMB | FreeS Family Funding News Vol.15
Looking forward to working alongside more outstanding founders.
A Complete Map of China's Industrial Investment: When the Gears of Fate Begin to Turn
Seven sectors, 200 investments, 500 funds — all in nine charts.
We Studied 1,000 Corporate Venture Capital Deals and Found That "Strategic Capital" Is a Myth
So what exactly is true industrial investment?
